| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Radiology and Medicine, University of Washington Medical Center, Seattle, Washington
Oak Ridge National Laboratories, Oak Ridge, Tennessee
Marion Merrell Dow, Indianapolis Indiana
Correspondence: For correspondence or reprints contact: Janet F. Eary, MD, Associate Professor, Radiology and Pathology, Division of Nuclear Medicine, University of Washington Medical Center, 1959 N.E. Pacific, Seattle, WA 98195.
ABSTRACT
Fifty-two patients were treated with single doses of 153Sm-EDTMP in a Phase I escalating dose protocol for palliation of bone pain from metastatic prostate carcinoma Samarium-153 (T1/2 46.3 hr), maximum ß- particle energies 810 keV (20%), 710 keV (30%), 640 keV (50%), gamma photon 103 keV (28%), was complexed to the tetraphosphonate chelate, EDTMP. Five groups of patents were treated at doses of 1.0, 1.5, 2.0, 2.5, and 3.0 mCi/kg to evaluate toxicity from treatment. Patients were screened prior to treatment and followed after treatment with 99mTc-MDP bone scans. Biodistribution data on the group of patients were acquired and showed rapid uptake of 153Sm-EDTMP into bone with complete clearance of nonskeletal radiotoxicity by 6–8 hr. Also included are complete sets of dosimetry estimations on an additional seven patients who received 0.5 mCi/kg 153Sm-EDTMP Ca++ as part of a multiple dose therapy trial. Estimated radiation absorbed doses to bone surfaces averaged 25,000 mrad/mCi (6686 Gy/MBq), and urinary bladder doses averaged 3600 mrad/mCi (964Gy/MBq).
This article has been cited by other articles:
|
|
 |
|
  M. Chakraborty, E. K. Wansley, J. A. Carrasquillo, S. Yu, C. H. Paik, K. Camphausen, M. D. Becker, W. F. Goeckeler, J. Schlom, and J. W. Hodge The Use of Chelated Radionuclide (Samarium-153-Ethylenediaminetetramethylenephosphonate) to Modulate Phenotype of Tumor Cells and Enhance T Cell-Mediated Killing Clin. Cancer Res., July 1, 2008; 14(13): 4241 - 4249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. B. Breitz, R. E. Wendt III, M. S. Stabin, S. Shen, W. D. Erwin, J. G. Rajendran, J. F. Eary, L. Durack, E. Delpassand, W. Martin, et al. 166Ho-DOTMP Radiation-Absorbed Dose Estimation for Skeletal Targeted Radiotherapy J. Nucl. Med., March 1, 2006; 47(3): 534 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Anderson, G. A. Wiseman, L. Erlandson, V. Rodriguez, B. Trotz, S. A. Dubansky, and K. Albritton Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma Clin. Cancer Res., October 1, 2005; 11(19): 6895 - 6900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Pandit-Taskar, M. Batraki, and C. R. Divgi Radiopharmaceutical Therapy for Palliation of Bone Pain from Osseous Metastases J. Nucl. Med., August 1, 2004; 45(8): 1358 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Smith, A. Navani, and S. M. Fishman Radiopharmaceuticals for palliation of painful osseous metastases American Journal of Hospice and Palliative Medicine, July 1, 2004; 21(4): 303 - 313. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Palmedo, A. Manka-Waluch, P. Albers, I. G.H. Schmidt-Wolf, M. Reinhardt, S. Ezziddin, A. Joe, R. Roedel, R. Fimmers, F.F. Knapp Jr, et al. Repeated Bone-Targeted Therapy for Hormone-Refractory Prostate Carcinoma: Randomized Phase II Trial With the New, High-Energy Radiopharmaceutical Rhenium-188 Hydroxyethylidenediphosphonate J. Clin. Oncol., August 1, 2003; 21(15): 2869 - 2875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Liepe, R. Hliscs, J. Kropp, R. Runge, F. F. Knapp Jr., and W.-G. Franke Dosimetry of 188Re-Hydroxyethylidene Diphosphonate in Human Prostate Cancer Skeletal Metastases J. Nucl. Med., June 1, 2003; 44(6): 953 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Brenner, W. U. Kampen, C. Brummer, C. von Forstner, M. Zuhayra, N. Czech, C. Muhle, and E. Henze Bone Uptake Studies in Rabbits Before and After High-Dose Treatment with 153Sm-EDTMP or 186Re-HEDP J. Nucl. Med., February 1, 2003; 44(2): 247 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Rajendran, J. F. Eary, W. Bensinger, L. D. Durack, C. Vernon, and A. Fritzberg High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation J. Nucl. Med., October 1, 2002; 43(10): 1383 - 1390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Anderson, G. A. Wiseman, A. Dispenzieri, C. A.S. Arndt, L. C. Hartmann, W. A. Smithson, B. P. Mullan, and O. S. Bruland High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases J. Clin. Oncol., January 1, 2002; 20(1): 189 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Serafini Therapy of Metastatic Bone Pain J. Nucl. Med., June 1, 2001; 42(6): 895 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Brenner, W. U. Kampen, A. M. Kampen, and E. Henze Skeletal Uptake and Soft-Tissue Retention of 186Re-HEDP and 153Sm-EDTMP in Patients with Metastatic Bone Disease J. Nucl. Med., February 1, 2001; 42(2): 230 - 236. [Abstract] [Full Text]
|
|
|
|
|
|
A. Bishayee, D. V. Rao, S. C. Srivastava, L. G. Bouchet, W. E. Bolch, and R. W. Howell Marrow-Sparing Effects of 117mSn(4+)Diethylenetriaminepentaacetic Acid for Radionuclide Therapy of Bone Cancer J. Nucl. Med., December 1, 2000; 41(12): 2043 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Graham, H. I. Scher, G.-B. Liu, S. D-J. Yeh, T. Curley, F. Daghighian, S. J. Goldsmith, and S. M. Larson Rhenium-186-labeled Hydroxyethylidene Diphosphonate Dosimetry and Dosing Guidelines for the Palliation of Skeletal Metastases from Androgen-independent Prostate Cancer Clin. Cancer Res., June 1, 1999; 5(6): 1307 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Rodriguez and D. Betcher 153Sm-EDTMP Journal of Pediatric Oncology Nursing, January 1, 1998; 15(2): 95 - 97. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
